Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Metastases
- Astrocytoma
- Bladder Cancer
- Prostate Cancer
- Melanoma
- Pancreatic Cancer
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Cholangiocarcinoma
- Colorectal Cancer
- Lung Cancer
- Tongue Cancer
- Sarcoma
- Thymic Carcinoma
- Liver Cancer
- Urinary Tract Cancer
- Esophagus Cancer
- Gastric Cancer
- Head and Neck Cancer
- Kidney Cancer
- Ovarian Cancer
- Pleural Mesothelioma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: The dose escalation scheme for this trial employs an mTPI-2 design.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04430842
- Collaborators
- Novotech (Australia) Pty Limited
- Investigators
- Not Provided
Get Well Soon